Enveric Biosciences, Inc.
For the period ended Aug 14, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 14, 2026 · Filed Aug 14, 2026
Use the contents to explore the available documents and sections.
ENVB$1.42+1.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · EB-003 Development:
EB-003 Development:
| ● | Reported highly sensitive GloSensor™ cAMP assay demonstrating that EB-003 consistently exhibited a differentiated non-hallucinogenic profile. |
| ○ | Data complement previously reported BRET assay findings that support Enveric’s differentiated approach to developing non-hallucinogenic neuroplastogenic therapeutics. |
| ● | Announced favorable in vitro study results demonstrating that EB-003 did not exhibit photoreactive potential, supporting its continued development as a potential chronic therapy for patients with neuropsychiatric disorders. |
| ● | Advanced IND-enabling activities through the initiation of genotoxicity studies, an important component of the preclinical safety package required to support submission of an IND application. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.